Evidence map›Paper›PMID 40229541›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2025

Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial.

Francesco Bavato, Laura K Schnider, Dario A Dornbierer, Julia R Di Floriano, Benjamin Stucky, Nicole Friedli, Marina Janki, Boris B Quednow, Hans-Peter Landolt, Oliver G Bosch and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Francesco BavatoDepartment of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland. francesco.bavato@bli.uzh.ch.ORCID http://orcid.org/0000-0002-3787-6706
Laura K SchniderInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0005-6332-5712
Dario A DornbiererDepartment of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.
Julia R Di FlorianoDepartment of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.
Benjamin StuckyInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-7425-2927
Nicole FriedliDepartment of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.
Marina JankiDepartment of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.
Boris B QuednowDepartment of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-7933-2865
Hans-Peter LandoltInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-0887-9403
Oliver G BoschDepartment of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-5807-0859
Erich SeifritzDepartment of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 175780Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 217637
6 · The paper itself

Abstract

In major depressive disorder (MDD), main clinical features include insomnia and increased daytime sleepiness. However, specific treatment options to promote sleep in MDD are limited. Gamma-hydroxybutyrate (GHB, administered as sodium oxybate) is a GHB/GABA

Indexed as

Major Depressive DisorderSleep, Slow-WaveSodium OxybateAdultAgedCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedPolysomnographyTrazodoneYoung AdultSodium OxybateTrazodone

Identifiers

PMID40229541
PMCPMC12170893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.